Crescent Biopharma/$CBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crescent Biopharma
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Ticker
$CBIO
Sector
Primary listing
Employees
6
Headquarters
Website
CBIO Metrics
BasicAdvanced
$192M
-
-$13.45
-
-
Price and volume
Market cap
$192M
52-week high
$21.40
52-week low
$10.83
Average daily volume
120K
Financial strength
Current ratio
3.62
Quick ratio
3.616
Long term debt to equity
-326.527
Total debt to equity
-326.527
Interest coverage (TTM)
-20.18%
Profitability
Management effectiveness
Valuation
Price to book
-6.28
Price to tangible book (TTM)
-6.28
Price to free cash flow (TTM)
-2.921
Free cash flow yield (TTM)
-34.23%
Free cash flow per share (TTM)
-4.721
Growth
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crescent Biopharma stock?
Crescent Biopharma (CBIO) has a market cap of $192M as of August 18, 2025.
What is the P/E ratio for Crescent Biopharma stock?
The price to earnings (P/E) ratio for Crescent Biopharma (CBIO) stock is 0 as of August 18, 2025.
Does Crescent Biopharma stock pay dividends?
No, Crescent Biopharma (CBIO) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Crescent Biopharma dividend payment date?
Crescent Biopharma (CBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Crescent Biopharma?
Crescent Biopharma (CBIO) does not currently have a Beta indicator.